Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study
dc.contributor.author | Virtanen, J. K. | en_US |
dc.contributor.author | Voutilainen, S. | en_US |
dc.contributor.author | Alfthan, G. | en_US |
dc.contributor.author | Korhonen, M. J. | en_US |
dc.contributor.author | Rissanen, Tiina H. | en_US |
dc.contributor.author | Mursu, J. | en_US |
dc.contributor.author | Kaplan, George A. | en_US |
dc.contributor.author | Salonen, Jukka T. | en_US |
dc.date.accessioned | 2010-06-01T20:06:38Z | |
dc.date.available | 2010-06-01T20:06:38Z | |
dc.date.issued | 2005-03 | en_US |
dc.identifier.citation | VIRTANEN, J. K.; VOUTILAINEN, S.; ALFTHAN, G.; KORHONEN, M. J.; RISSANEN, T. H.; MURSU, J.; KAPLAN, G. A.; SALONEN, J. T. (2005). "Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study." Journal of Internal Medicine 257(3): 255-262. <http://hdl.handle.net/2027.42/73235> | en_US |
dc.identifier.issn | 0954-6820 | en_US |
dc.identifier.issn | 1365-2796 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/73235 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15715682&dopt=citation | en_US |
dc.format.extent | 107059 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Ltd | en_US |
dc.rights | 2005 Blackwell Publishing Ltd | en_US |
dc.subject.other | Cardiovascular Disease | en_US |
dc.subject.other | Homocysteine | en_US |
dc.subject.other | Interaction | en_US |
dc.subject.other | Prospective Studies | en_US |
dc.subject.other | Risk Factors | en_US |
dc.title | Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Research Institute of Public Health, University of Kuopio, Kuopio | en_US |
dc.contributor.affiliationother | Biomarker Laboratory, National Public Health Institute, Helsinki | en_US |
dc.contributor.affiliationother | Department of Public Health and General Practice, University of Kuopio, Kuopio, Finland | en_US |
dc.contributor.affiliationother | Oy Jurilab Ltd, Kuopio, Finland | en_US |
dc.identifier.pmid | 15715682 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/73235/1/j.1365-2796.2005.01450.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2796.2005.01450.x | en_US |
dc.identifier.source | Journal of Internal Medicine | en_US |
dc.identifier.citedreference | Mangoni AA, Jackson SHD. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002; 112: 556 – 65. | en_US |
dc.identifier.citedreference | Voutilainen S, Lakka TA, HÄmelahti P, LehtimÄki T, Poulsen HE, Salonen JT. Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. J Intern Med 2000; 248: 217 – 22. | en_US |
dc.identifier.citedreference | Alfthan G, Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9 – 19. | en_US |
dc.identifier.citedreference | Knekt P, Reunanen A, Alfthan G et al. Hyperhomocystinemia. A risk factor or a consequence of coronary heart disease ? Arch Intern Med 2001; 161: 1589 – 94. | en_US |
dc.identifier.citedreference | Woo KS, Chook P, Lolin Y et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542 – 4. | en_US |
dc.identifier.citedreference | Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042 – 50. | en_US |
dc.identifier.citedreference | Glueck CJ, Shaw P, Land JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75: 132 – 6. | en_US |
dc.identifier.citedreference | Schlaich MP, John S, Jacobi J, Lackner KJ, Schmieder RE. Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients. Atherosclerosis 2000; 153: 383 – 9. | en_US |
dc.identifier.citedreference | Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 2002; 22: 1042 – 5. | en_US |
dc.identifier.citedreference | O'Callaghan P, Meleady R, Fitzgerald T, Graham I, the European COMAC group. Smoking and plasma homocysteine. Eur Heart J 2002; 23: 1580 – 6. | en_US |
dc.identifier.citedreference | Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study. Am J Clin Nutr 1998; 67: 263 – 70. | en_US |
dc.identifier.citedreference | Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026 – 33. | en_US |
dc.identifier.citedreference | Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 1988; 20: 46 – 50. | en_US |
dc.identifier.citedreference | Schwab U, TÖrrÖnen A, Toppinen L et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr 2002; 76: 961 – 7. | en_US |
dc.identifier.citedreference | Salonen JT, NyyssÖnen K, Korpela H, Tuomilehto J, SeppÄnen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 803 – 11. | en_US |
dc.identifier.citedreference | Salonen JT, Salonen R, SeppÄnen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfraction, and the risk of acute myocardial infarction: a prospective population study in eastern Finnish men. Circulation 1991; 84: 129 – 39. | en_US |
dc.identifier.citedreference | Salonen JT, SeppÄnen K, NyyssÖnen K et al. Intake of mercury from fish, lipid peroxidation and the risk of myocardial infarction and coronary, cardiovascular and any death in eastern Finnish men. Circulation 1995; 91: 645 – 55. | en_US |
dc.identifier.citedreference | Vollset SE, Refsum H, Tverdal A et al. Plasma total homocysteine and cardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 2001; 74: 130 – 6. | en_US |
dc.identifier.citedreference | Bostom AG, Silbershatz H, Rosenberg IH et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingam men and women. Arch Intern Med 1999; 159: 1077 – 80. | en_US |
dc.identifier.citedreference | Blacher J, Benetos A, Kirzin JM, Malejac A, Guize L, Safar ME. Relation of plasma total homocysteine to cardiovascular mortality in a French population. Am J Cardiol 2002; 90: 591 – 5. | en_US |
dc.identifier.citedreference | Greenland S. Modelling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79: 340 – 9. | en_US |
dc.identifier.citedreference | Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700 – 7. | en_US |
dc.identifier.citedreference | Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956 – 63. | en_US |
dc.identifier.citedreference | Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002; 53: 538 – 49. | en_US |
dc.identifier.citedreference | Chowienczyk PJ, Watts GF, Cockkroft JR, Ritte JM. Impaired endothelium-dependent vasodilatation of forearm resistance vessels in hypercholesterolemia. Lancet 1992; 340: 1430 – 2. | en_US |
dc.identifier.citedreference | Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496 – 500. | en_US |
dc.identifier.citedreference | Vaudo G, Marchesi S, Siepi D et al. Relevance of homocysteine on brachial flow-mediated vasodilatation and carotid and femoral intima-media thickness in patients with hypercholesterolemia. Am J Cardiol 2004; 93: 1413 – 6. | en_US |
dc.identifier.citedreference | Mannucci PM. Recent progress in the pathophysiology of fibrinogen. Eur Heart J 1995; 16: 25 – 30. | en_US |
dc.identifier.citedreference | Norio R. Diseases in Finland and Scandinavia. In: Rothscild HR, ed. Biocultural Aspects of Disease. Orlando, FL: Academic Press Inc., 1981; 358 – 415. | en_US |
dc.identifier.citedreference | BrattstrÖm L, Wilcken DEL, Öhrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The result of a meta-analysis. Circulation 1998; 98: 2520 – 6. | en_US |
dc.identifier.citedreference | Rady PL, Tyring SK, Hudnall SD et al. Methylenetetrahydrofolate reductase (MTHFR): the incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. Am J Med Genet 1999; 86: 380 – 4. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.